MedPath

JSKN-003

Generic Name
JSKN-003

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Oct 21, 2025

JSKN-003: A Comprehensive Clinical and Scientific Dossier

Executive Summary

JSKN-003 is an investigational, next-generation antibody-drug conjugate (ADC) engineered to target the human epidermal growth factor receptor 2 (HER2). Developed by Alphamab Oncology, it represents a significant evolution in ADC technology, integrating multiple proprietary innovations to enhance efficacy and broaden the therapeutic window.[1] The core structure of JSKN-003 is built upon KN026, a biparatopic antibody that uniquely binds to two distinct epitopes on the HER2 receptor. This antibody is site-specifically conjugated to a potent topoisomerase I inhibitor payload using a proprietary glycan-specific platform, resulting in a highly stable and homogenous therapeutic agent with a powerful bystander effect.[1]

The clinical development program for JSKN-003 has yielded compelling data across multiple heavily pretreated solid tumor indications, most notably in platinum-resistant ovarian cancer (PROC) and HER2-positive breast cancer. In a pooled analysis of patients with PROC, JSKN-003 demonstrated a transformative objective response rate (ORR) of 64.4% and a median progression-free survival (PFS) of 7.1 months, far exceeding historical benchmarks for standard-of-care chemotherapy.[3] A landmark finding from these studies is the drug's profound activity in patients with HER2-negative (immunohistochemistry [IHC] 0) tumors, challenging the conventional biomarker-driven paradigm for HER2-targeted agents and suggesting a potential HER2-agnostic role in this setting.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.